Velosef

Osteomyelitis, Peritonitis, Urinary Tract Infections + 5 more

Treatment

4 Active Studies for Velosef

What is Velosef

Cefradine

The Generic name of this drug

Treatment Summary

A type of antibiotic that is a combination of synthetic and naturally occurring ingredients.

Velosef

is the brand name

Velosef Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Velosef

Cefradine

1995

4

Effectiveness

How Velosef works in the body

Cefradine is an antibiotic that works by blocking the formation of bacterial cell walls. It attaches to proteins inside the cell wall and prevents it from fully forming. This causes the cell wall to break apart, leading to the death of the bacteria. It also might stop an enzyme from protecting the cell wall, making it even easier for the wall to break down.

When to interrupt dosage

The suggested dose of Velosef is contingent upon the diagnosed affliction, including Respiratory Tract Infections, Septic Arthritis and Sepsis Bacterial. The dosage amount oscillates based on the administration technique (e.g. Suspension or Capsule, gelatin coated - Oral) denoted in the table beneath.

Condition

Dosage

Administration

Urinary Tract Infections

500.0 mg, , 250.0 mg, 125.0 mg/mL, 250.0 mg/mL

Capsule, gelatin coated, , Oral, Capsule, gelatin coated - Oral, Suspension, Suspension - Oral

Osteomyelitis

500.0 mg, , 250.0 mg, 125.0 mg/mL, 250.0 mg/mL

Capsule, gelatin coated, , Oral, Capsule, gelatin coated - Oral, Suspension, Suspension - Oral

Peritonitis

500.0 mg, , 250.0 mg, 125.0 mg/mL, 250.0 mg/mL

Capsule, gelatin coated, , Oral, Capsule, gelatin coated - Oral, Suspension, Suspension - Oral

Respiratory Tract Infections

500.0 mg, , 250.0 mg, 125.0 mg/mL, 250.0 mg/mL

Capsule, gelatin coated, , Oral, Capsule, gelatin coated - Oral, Suspension, Suspension - Oral

Arthritis, Infectious

500.0 mg, , 250.0 mg, 125.0 mg/mL, 250.0 mg/mL

Capsule, gelatin coated, , Oral, Capsule, gelatin coated - Oral, Suspension, Suspension - Oral

Sepsis

500.0 mg, , 250.0 mg, 125.0 mg/mL, 250.0 mg/mL

Capsule, gelatin coated, , Oral, Capsule, gelatin coated - Oral, Suspension, Suspension - Oral

Sepsis

500.0 mg, , 250.0 mg, 125.0 mg/mL, 250.0 mg/mL

Capsule, gelatin coated, , Oral, Capsule, gelatin coated - Oral, Suspension, Suspension - Oral

Communicable Diseases

500.0 mg, , 250.0 mg, 125.0 mg/mL, 250.0 mg/mL

Capsule, gelatin coated, , Oral, Capsule, gelatin coated - Oral, Suspension, Suspension - Oral

Warnings

Velosef has two contraindications, hence it should not be taken when enduring any of the conditions delineated in the following table.

Velosef Contraindications

Condition

Risk Level

Notes

Bacterial Meningitis

Do Not Combine

known hypersensitivity to the drug or any of the ingredients

Do Not Combine

There are 20 known major drug interactions with Velosef.

Common Velosef Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The metabolism of Abemaciclib can be increased when combined with Cefradine.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be increased when combined with Cefradine.

Alectinib

Major

The metabolism of Alectinib can be increased when combined with Cefradine.

Alpelisib

Major

The metabolism of Alpelisib can be increased when combined with Cefradine.

Aminophylline

Major

The metabolism of Aminophylline can be increased when combined with Cefradine.

image of a doctor in a lab doing drug, clinical research

Velosef Novel Uses: Which Conditions Have a Clinical Trial Featuring Velosef?

Currently, 15 active trials are being conducted to assess the potential of Velosef to combat Sepsis, Septic Arthritis and Peritonitis.

Condition

Clinical Trials

Trial Phases

Arthritis, Infectious

0 Actively Recruiting

Communicable Diseases

0 Actively Recruiting

Osteomyelitis

2 Actively Recruiting

Phase 2, Not Applicable

Respiratory Tract Infections

2 Actively Recruiting

Phase 3, Not Applicable

Sepsis

0 Actively Recruiting

Sepsis

0 Actively Recruiting

Peritonitis

0 Actively Recruiting

Urinary Tract Infections

0 Actively Recruiting

Velosef Reviews: What are patients saying about Velosef?

3.7

Patient Review

3/30/2010

Velosef for Acute Infection of the Nose, Throat or Sinus

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about velosef

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Velosef tablet used for?

"Velosef is an antibiotic used to treat bacterial infections. It is a cephalosporin type of antibiotic that belongs to the beta-lactam group of antibiotics and works by stopping the production of the bacterial walls."

Answered by AI

Is Velosef an antibiotic?

"Velosef is a semi-synthetic cephalosporin antibiotic. It comes in the form of capsules containing 250 mg and 500 mg cephradine, and a suspension containing 125 mg and 250 mg per 5 mL dose."

Answered by AI

What is Cefradine used to treat?

"Cefradine 500mg caps can help treat bacterial infections of the respiratory and urinary tracts, as well as the skin and soft tissues. This includes infections such as sinusitis, pharyngitis, tonsillitis, laryngo-tracheo bronchitis and otitis media."

Answered by AI

What are the side effects of Velosef?

"Stomach-related side effects like nausea, vomiting, and diarrhea are some of the most commonly reported problems with cephradine. A few people taking the drug have also developed a serious condition called pseudomembranous colitis."

Answered by AI

Clinical Trials for Velosef

Image of Seattle Children's Hospital in Seattle, United States.

Follow-Up Strategies for Children With Medical Complexity

1 - 16
All Sexes
Seattle, WA

Children with medical complexity often receive a recommendation to see an outpatient clinician soon after leaving the hospital. It is uncertain whether every child needs this routine visit or whether follow-up can be guided by the family's concerns and the child's recovery. AFTERCARE is a multicenter pilot randomized trial comparing these two follow-up recommendations for children hospitalized with an acute infection. Families will be assigned by chance to receive either a recommendation to arrange follow-up with their usual outpatient clinician within seven days or a recommendation to seek follow-up if the child is not improving as expected or new concerns arise. Families in both groups may seek medical care whenever needed. The study will assess recruitment, follow-up data collection, delivery of the recommendations and acceptability. Caregiver surveys and medical record review will also describe outpatient visits and hospital returns. This pilot will inform the design of a larger trial, and is not designed to establish that the strategies are equally safe or effective.

Waitlist Available
Has No Placebo

Seattle Children's Hospital

Nassr Nama, MD, MSc